Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06836609 | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | PHASE1 | RECRUITING | 132 | — | — | Apr 28, 2025 | May 15, 2027 | Apr 27, 2026 | 3 | United States, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Randomized per the protocol |
| Part B | EXPERIMENTAL | Randomized per the protocol |
| Name | Type | Description |
|---|---|---|
| ALN-CIDEB | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Part A: 18 to 55 years at Screening Visit 1 with MASLD, at Screening Visit 1 Part B: 18 to 65 years at Screening Visit 1 with a diagnosis of MASH, at Screening Visit 1 2. Body Mass Index (BMI) ≥30 kg/m2 and ≤40 kg/m2 at Screening Visit 1 3. Controlled-Attenuation Paramete...